This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why Abbott (ABT) Fell More Than Broader Market
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $113.70, moving -0.39% from the previous trading session.
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
by Zacks Equity Research
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.
PAHC vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Abbott (ABT) reachead $117.63 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
High Tide Inc. (HITI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
High Tide (HITI) delivered earnings and revenue surprises of 150% and 2.50%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Roche Stock to Benefit From Accu-Chek Smartguide Launch in Europe
by Zacks Equity Research
RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device may face tough competition from existing CGM devices.
Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?
by Urmimala Biswas
MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.
Why Abbott (ABT) Outpaced the Stock Market Today
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $117.11, marking a +0.58% move from the previous day.
Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
by Zacks Equity Research
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
by Zacks Equity Research
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Continue to Retain ABT Stock in Your Portfolio Now?
by Zacks Equity Research
Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $114.66, marking a +1.23% move from the previous day.
PAHC vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Stock Moves -0.18%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $112.90, moving -0.18% from the previous trading session.
ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition
by Zacks Equity Research
Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.
DexCom Stock May Gain on Expanded Reach After Stelo's US Launch
by Zacks Equity Research
DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.
Abbott's Core Businesses Thrive Despite Macroeconomic Issues
by Zacks Equity Research
ABT is particularly gaining from the strong adoption of its market leading systems and demand for testing that takes place in a variety of settings.
The Zacks Analyst Blog Eli Lilly, Chevron, Abbott and Bridger Aerospace
by Zacks Equity Research
Eli Lilly, Chevron, Abbott and Bridger Aerospace are included in this Analyst Blog.
Top Research Reports for Eli Lilly, Chevron & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Chevron Corporation (CVX) and Abbott Laboratories (ABT), as well as a micro-cap stocks Bridger Aerospace Group Holdings, Inc. (BAER).
Why Is Boston Scientific (BSX) Up 7.2% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
by Zacks Equity Research
Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.
Abbott (ABT) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $112.10, moving +0.64% from the previous trading session.